Onkologie. 2023:17(3):160-163 | DOI: 10.36290/xon.2023.032

Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer

Markéta Palácová
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

Triple negative breast cancer (TNBC) continues to have the worst prognosis compared to other phenotypes. However, in the last 2 years it has been shining on better times. In addition to chemotherapy, new treatment options for metastatic disease - immunotherapy, PARP inhibitors and monoclonal antibody conjugate with cytostatic - sacituzumab govitekan have entered clinical practice. This drug demonstrated effectiveness not only in the progression free survival, but also in overall survival. Sacituzumab govitekan was introduced into clinical practice by the ASCENT registration study. Adverse events should be monitored for the most frequent occurrence of neutropenia, nausea and diarrhoea.

Keywords: TNBC, metastatické onemocnění, sacituzumab govitekan, toxicita.

Accepted: June 12, 2023; Published: June 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Palácová M. Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer. Onkologie. 2023;17(3):160-163. doi: 10.36290/xon.2023.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Howlader N, Noone AM, Krapcho M, et al. Cancer statistic review. 1975-2016-SEER Statistics: SEER web site; 2019.
    2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer res. 2007;13(15):4429-4434. Go to original source... Go to PubMed...
    3. Lehmann B, Bauer J, Chen X, et al. Identification of humna triple.negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750-2767. Go to original source... Go to PubMed...
    4. Burnstein M, Tsimelzon A, Poage G, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin cancer Res. 2015;21(7):1688-1698. Go to original source... Go to PubMed...
    5. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion 130): updated efficacy results from a randomised, double-b, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59. Go to original source... Go to PubMed...
    6. Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(15suppl):1000. Go to original source...
    7. Bardia A, Hurvitz SA, Tolenay SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529-1541. Go to original source... Go to PubMed...
    8. Modrá kniha 2023. Available from: www.linkos.cz.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.